Dr Maren Schubert

Dr. Maren Schubert (née Bleckmann) studied biotechnology at the TU Braunschweig and obtained her PhD at the HZI in 2016 in the group for Recombinant Protein Expression. During her PhD, she developed a novel baculovirus-free expression system for insect cells as well as cell-based screening assays. She then became head of the recombinant protein expression platform at the Rudolf Virchow Centre in Würzburg, where she was responsible for the production of various proteins for different projects. In 2018, she returned to the TU Braunschweig to work on antigen and antibody expression systems and the development of cellular assays in the Department of Biotechnology. The SARS-CoV-2 antigens produced in her insect cell system were applied e.g. for the development of anti-COVID-19 antibodies (COR101, NCT04674566) and in various diagnostic studies. In addition, she developed virus-like particle (VLP)-based systems for the generation, evaluation and development of monoclonal antibodies. In September 2025, she is now back at the HZI as HUMAN junior research group leader and focuses on VLP-based technologies to successfully fight infectious diseases.